Patients who have non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations (EGFRm ex20ins NSCLC) have a 75% increased risk of death (HR=1.75) compared to patients who have common EGFR-tyrosine kinase inhibitor (EGFR-TKI) sensitive mutations* in their tumours (median OS 16.2 vs 25.5 months, respectively). The precious time that patients have left is often tainted by the negative emotional burden of the disease.**
Patients with EGFRm ex20ins NSCLC generally experience limited outcomes with currently approved EGFR-TKIs. In fact, response rates of these patients to EGFR-TKIs are approximately one third of those observed in patients who have EGFRm NSCLC without an ex20ins mutation.†,
Due to the lack of effective targeted options, patients with EGFRm ex20ins NSCLC are most commonly prescribed chemotherapies as a first-line treatment, which are non-selective and have a wide range of side effects.
* EGFR exon 19 deletions and EGFR L858R point mutation.
** Qualitative interviews conducted with patients with NSCLC that had EGFR exon 20 mutations (n=10), 90% of whom had exon 20 insertion mutations. 100% of participants with EGFRm ex20ins NSCLC reported a psychological or emotional burden of their disease, and 60% described worries around treatment, the future, or finances.
† Data taken from a meta-analysis of 61 studies, 12 of which reported overall response rate (ORR) in patients with EGFRm ex20ins NSCLC. Patient numbers not reported. Mean ORR of patients with EGFRm NSCLC, without a detectable ex20ins mutation to EGFR-TKIs= 34.0% (13.9–84%). Mean ORR of patients with EGFRm ex20ins NSCLC to EGFR-TKIs= 11.9% (0.0–35.0%).
EGFR, epidermal growth factor receptor; EGFRm, mutated EGFR; EGFR-TKI, EGFR-tyrosine kinase inhibitor; ex20ins, exon 20 insertion; HR, hazard ratio; mOS, median overall survival; NSCLC, non-small cell lung cancer; ORR, overall response rate.